Clinical-stage biopharmaceutical firm Createrna Science & Technology has notched 500 million yuan ($69.7 million) in a Series A financing round led by the life science-focused venture capital firm Lilly Asia Ventures (LAV).
The round was also participated by the Chinese venture capital firm Vinno Capital, which invests in the IT and healthcare sectors. The fresh funds will help the Wuhan-based Createrna Science & Technology accelerate R&D and advance clinical research, it said in a release.